TriSalus Life Sciences, Inc. Warrant Form 4 Filings

TriSalus Life Sciences CEO Mary T. Szela reported an acquisition of 3,990 shares of common stock. These shares were obtained at $3.87 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this grant, she directly holds 1,077,683 TriSalus shares.

TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.8700 per share. The shares were obtained through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this award, he directly holds 128,319 shares.

TriSalus Life Sciences, Inc. Chief Medical Officer Richard Henry received new equity compensation in the form of restricted stock units and stock options. He was granted 60,000 shares of common stock as restricted stock units, which will vest in four equal annual installments starting on June 29, 2027, assuming continued service. He also received an employee stock option for 120,000 shares of common stock at an exercise price of $4.74 per share, vesting over four years with one-fourth vesting on June 29, 2027 and the remainder monthly thereafter. Following these grants, he directly holds 90,000 shares of common stock and 253,000 stock options.

TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.

TriSalus Life Sciences director Mats Wahlstrom bought additional common stock in the open market. He acquired 60,000 shares at a weighted average price of $2.53 per share, with individual trades priced between $2.52 and $2.56. Following this purchase, he holds 147,555 shares directly.

Wahlstrom is also associated with significant indirect holdings. HW Investment Partners, LLC holds 1,370,028 shares, where he is a managing member and he disclaims beneficial ownership beyond his economic interest. Leonard Capital LLC holds 1,444,447 shares, over which he and his spouse share voting and investment discretion.

TriSalus Life Sciences director Michael P. Stansky reported significant open-market buying of the company’s common stock. On May 15, 2026, an entity he manages, Skyview Investments LLC, purchased 200,000 shares at a weighted average price of $2.50 per share, bringing its holdings to 399,698 shares held indirectly. On the same date, he also purchased 410,000 shares directly at a weighted average price of $2.50 per share, increasing his direct ownership to 1,240,722 shares. The filing notes that each block was acquired through multiple trades within stated price ranges.

TriSalus Life Sciences CEO Mary T. Szela bought 39,682 shares of common stock in an open-market purchase at a weighted average price of $2.59 per share. After this transaction, she directly holds 1,065,215 common shares.

A footnote explains these purchases are matchable under Section 16(b) against earlier sales that were made solely to cover tax withholding on vesting restricted stock units. The filing states she paid $27,573.70 to the company, equal to the profit from this short-swing transaction.

TriSalus Life Sciences Chief Financial Officer Patience David bought 7,100 shares of the company’s Common Stock in an open-market transaction at $2.43 per share on May 15, 2026. Following this purchase, she directly owns 275,757 Common Stock shares.

TriSalus Life Sciences director Kerry R. Hicks reported new equity awards and updated holdings. Hicks received 28,201 restricted stock units payable in common stock, which fully vest on May 14, 2026, subject to continued service. He was also granted 56,403 director stock options with a $2.52 exercise price, expiring on May 13, 2036, that vest on the same date. Following these grants, Hicks directly holds 542,790 shares of common stock and 145,625 director stock options. Indirect holdings include 1,370,028 shares through HW Investment Partners, LLC, 322,737 shares via The Kerry Raymond Hicks Dynasty Trust, and 81,845 shares held by Millennium Trust Company, LLC, with beneficial ownership in certain entities disclaimed except for his pecuniary interest.

TriSalus Life Sciences director Mats Wahlstrom reported new equity compensation grants. He received 34,226 restricted stock units that vest fully on May 14, 2026, payable in common stock, subject to his continued board service.

He also received a Retainer RSU Award of 37,602 units, taken in lieu of 2026 cash board retainer fees. These RSUs vest in three equal quarterly installments through the remainder of 2026, conditioned on continued service. In addition, he was granted a director stock option for 75,204 shares of common stock at an exercise price of $2.5200 per share, vesting in full on May 14, 2026 and expiring on May 13, 2036.

The filing also shows substantial indirect common stock holdings through Leonard Capital LLC and HW Investment Partners, LLC, where Wahlstrom shares voting and investment discretion, and he disclaims beneficial ownership of HW Investment securities beyond his pecuniary interest.

TriSalus Life Sciences director Gary B. Gordon received equity awards in the form of common stock and stock options. The filing reports grants of 24,553 and 28,201 shares of common stock at a price of $0.00 per share, reflecting restricted stock unit awards.

One RSU award fully vests on the one-year anniversary of the grant date of May 14, 2026, while a separate retainer RSU award vests in three equal quarterly installments through the remainder of 2026, in lieu of cash board fees. In addition, Gordon received a director stock option covering 56,403 shares of common stock at an exercise price of $2.52 per share, expiring in 2036, which also fully vests on the one-year anniversary of the grant date.

TriSalus Life Sciences director David J. Matlin reported equity compensation grants. He received 23,065 restricted stock units that vest in full on the one-year anniversary of the May 14, 2026 grant date, subject to continued service.

He also received 28,201 restricted stock units in lieu of 2026 board service retainer cash fees; these vest in three equal quarterly installments through the remainder of 2026, subject to continued service. In addition, he was granted options to purchase 56,403 shares of common stock at an exercise price of $2.52 per share, vesting in full on the one-year anniversary of the May 14, 2026 grant date. Following these awards, Matlin directly holds 1,323,210 shares of common stock and 121,403 stock options.

TriSalus Life Sciences director William Valle reported equity compensation grants. He received 24,553 restricted stock units and 28,201 additional restricted stock units, both payable in common stock. One award is in lieu of 2026 board retainer cash fees and vests in quarterly one-third installments through 2026.

Valle was also granted a director stock option for 56,403 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036. The RSU awards and option generally vest on the one-year anniversary of the May 14, 2026 grant date, subject to his continued service with the company.

TriSalus Life Sciences director Michael P. Stansky reported new equity awards and updated holdings. He received two grants of restricted stock units covering 20,089 and 23,501 shares of common stock, both payable solely in stock. One RSU award vests fully on the one-year anniversary of the May 14, 2026 grant date, while the retainer RSU award vests in three equal quarterly installments through the remainder of 2026, each subject to his continued board service.

He was also granted a director stock option for 47,003 shares of common stock at an exercise price of $2.52 per share, expiring on May 13, 2036, which will fully vest one year after the grant date if he continues serving. Following these grants, he holds 830,722 common shares directly and 199,698 shares indirectly through Skyview Investments LLC, where he serves as managing member with voting and dispositive power, along with 139,540 director stock options.

Frankenius Equity AB, a more than 10% holder of TriSalus Life Sciences, Inc., converted its entire Series A Convertible Preferred Stock into common shares. On July 31, 2025, it exchanged 230,000 preferred shares for 759,000 shares of common stock under a company exchange offer.

The offer calculates common shares using the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Frankenius Equity directly holds 6,989,748 TriSalus common shares, replacing its prior preferred position with ordinary equity.

TriSalus Life Sciences director David J. Matlin converted preferred stock into common shares under a company offer. On July 31, 2025, all 100,000 shares of Series A Preferred Stock held by Matlin were converted into 330,000 shares of common stock.

The conversion followed an exchange offer allowing all preferred holders to receive common shares equal to the liquidation preference of $10.00 per preferred share plus accrued and unpaid dividends through August 10, 2027, divided by a $4.00 conversion price per share. After the conversion, Matlin directly owned 1,271,944 common shares and no remaining preferred shares.

TriSalus Life Sciences, Inc. executive Jodi Devlin, Chief of Clinical Operations, reported three transactions in common stock. Across 3,207 shares, stock was sold at prices between $4.09 and $4.13 per share to satisfy tax withholding obligations tied to previously vested restricted stock units. A footnote explains these sales were made solely to cover taxes and were not discretionary. Following the most recent transaction, Devlin directly holds 97,364 shares of TriSalus common stock.

TriSalus Life Sciences Chief of Research Bryan F. Cox reported automatic sales of common stock to cover taxes on vested restricted stock units. Across three trades on March 11, 12 and 16, 2026, a total of 3,184 shares were sold around $4.09–$4.13 per share, leaving him with 163,415 directly held shares. A footnote explains these sales were solely to satisfy tax withholding obligations and were not discretionary.

TriSalus Life Sciences Chief Commercial Officer Richard Marshak reported routine share disposals tied to tax withholding, not discretionary selling. Over three days, he disposed of a total of 3,457 shares of common stock at prices between $4.09 and $4.13 per share. A footnote explains these shares were sold solely to satisfy tax obligations from vesting restricted stock units previously granted to him. After these transactions, Marshak continues to hold 110,397 shares of TriSalus common stock directly, indicating the disposals are small relative to his remaining stake.

TriSalus Life Sciences Chief Regulatory Officer Jennifer Stevens reported routine share sales tied to tax withholding. She sold a total of 3,530 shares of common stock in open-market transactions between March 11 and March 16 at prices around $4.09–$4.13 per share.

According to the disclosure, the shares were sold solely to satisfy tax obligations from vesting restricted stock units and do not represent discretionary sales. After these transactions, she continues to hold 124,110 TriSalus shares directly.

TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported an open-market purchase of 3,657 shares of common stock at $4.10 per share. Following this transaction, his directly owned stake increased to 268,657 shares, signaling additional personal capital committed to the company.

TriSalus Life Sciences director Gary B. Gordon purchased 9,756 shares of the company’s common stock in an open-market transaction at $4.10 per share on February 23, 2026. Following this purchase, he directly owns 9,756 common shares of TriSalus Life Sciences, Inc.

TriSalus Life Sciences director William Valle reported an open-market purchase of company stock. On this Form 4, he bought 30,487 shares of TriSalus Life Sciences, Inc. common stock at a price of $4.10 per share. Following this transaction, he directly owns 30,487 common shares.

TriSalus Life Sciences CEO Mary T. Szela reported an open-market purchase of 30,487 shares of common stock at $4.10 per share. After this buy, she directly owns 773,289 shares, increasing her personal stake in the company.

TriSalus Life Sciences director Michael P. Stansky reported significant open-market purchases of the company’s common stock. He bought 243,900 shares directly at $4.10 per share and 117,198 shares at $4.10 per share through Skyview Investments LLC.

After these transactions, his direct holdings total 787,132 common shares, and his indirect holdings through Skyview Investments LLC total 199,698 common shares, reflecting continued equity ownership aligned with the company’s shareholders.

TriSalus Life Sciences, Inc. director Michael P. Stansky reported receiving a grant of stock options to buy 92,537 shares of common stock at an exercise price of $4.91 per share. The options vest in three equal annual installments starting on February 4, 2027, contingent on his continued service with the company.